Zentalis Pharmaceuticals Valuation
| ZNTL Stock | USD 1.76 0.11 5.88% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Zentalis Pharmaceuticals maintains a prevalent Real Value of $3.68 per share. The last-minute price of the company is $1.76. Our model calculates the value of Zentalis Pharmaceuticals from examining the company fundamentals such as Operating Margin of (5.16) %, return on asset of -0.25, and Shares Outstanding of 71.27 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Zentalis Pharmaceuticals' valuation include:
Price Book 0.3982 | Enterprise Value | Enterprise Value Ebitda (2.31) | Price Sales 3.4789 | Enterprise Value Revenue 7.7683 |
Undervalued
Today
Please note that Zentalis Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Zentalis Pharmaceuticals is based on 3 months time horizon. Increasing Zentalis Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Zentalis stock is determined by what a typical buyer is willing to pay for full or partial control of Zentalis Pharmaceuticals Llc. Since Zentalis Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Zentalis Stock. However, Zentalis Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.76 | Real 3.68 | Target 9.5 | Hype 1.77 | Naive 2.23 |
The intrinsic value of Zentalis Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Zentalis Pharmaceuticals' stock price.
Estimating the potential upside or downside of Zentalis Pharmaceuticals Llc helps investors to forecast how Zentalis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Zentalis Pharmaceuticals more accurately as focusing exclusively on Zentalis Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Zentalis Pharmaceuticals' intrinsic value based on its ongoing forecasts of Zentalis Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Zentalis Pharmaceuticals' closest peers.
Zentalis Pharmaceuticals Cash |
|
Zentalis Valuation Trend
Knowing Zentalis Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Zentalis Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Zentalis Pharmaceuticals Total Value Analysis
Zentalis Pharmaceuticals Llc is at this time anticipated to have valuation of (209.69 M) with market capitalization of 141.11 M, debt of 43.15 M, and cash on hands of 455.22 M. The negative valuation of Zentalis Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Zentalis Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(209.69 M) | 141.11 M | 43.15 M | 455.22 M |
Zentalis Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Zentalis is to check how much profit was generated for every dollar of assets it reports. Zentalis Pharmaceuticals maintains a negative usage of resources of -0.25 (%), losing $0.002524 for each dollar of resources held by the company. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it maintains. Specifically, asset utilization of Zentalis Pharmaceuticals Llc shows how discouraging it operates for each dollar spent on its resources.Zentalis Pharmaceuticals Ownership Allocation
Zentalis Pharmaceuticals Llc retains a total of 71.27 Million outstanding shares. The majority of Zentalis Pharmaceuticals outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zentalis Pharmaceuticals to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zentalis Pharmaceuticals Llc. Please pay attention to any change in the institutional holdings of Zentalis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost six million four hundred seventy-eight thousand twenty-five invesors are currently shorting Zentalis Pharmaceuticals expressing very little confidence in its future performance.Zentalis Pharmaceuticals Profitability Analysis
Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 40.56 M.About Zentalis Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Zentalis Pharmaceuticals Llc. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Zentalis Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Zentalis Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Zentalis Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Zentalis Pharmaceuticals. We calculate exposure to Zentalis Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Zentalis Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.3 M | -1.2 M | |
| Pretax Profit Margin | -1.5 K | -1.6 K | |
| Operating Profit Margin | -1.5 K | -1.6 K | |
| Net Loss | -1.4 K | -1.4 K |
Zentalis Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Zentalis Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 65.4 M |
Zentalis Pharmaceuticals Current Valuation Indicators
Zentalis Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Zentalis Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Zentalis Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Zentalis Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Zentalis Pharmaceuticals' worth.When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.